Aethlon Medical, Inc, a therapeutic technology company focused on unmet needs in global health, has received a “Breakthrough Device” designation from the US Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier for the treatment of cancer. The Aethlon Hemopurifier is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and life-threatening viruses.
Ook interessant voor je
![[onderzoek] Marketeers balanceren tussen AI en authentieke merkbeleving](https://www.pharmamarketeer.nl/wp-content/uploads/2025/03/167284-385x300.jpg)
![[onderzoek] Marketeers balanceren tussen AI en authentieke merkbeleving](https://www.pharmamarketeer.nl/wp-content/uploads/2025/03/167284-80x60.jpg)
